9th CDD For Biologics Summit 2024

Integrate Computational Biology, Generative AI & Machine Learning to Revolutionize Biologics Drug Discovery & Development

For the past eight years, the CDD for Biologics Summit has united computational and structural biologists, along with protein and antibody engineers, to showcase emerging computational programs and models aimed at revolutionizing biologics drug discovery and development.

With the transformative impact of AI-driven approaches in enhancing predictability, optimizing molecular design, and mitigating inherent risks in drug development pipelines, the summit is an indispensable platform for industry leaders to collaborate, innovate, and propel drug discovery forward amidst this era of computational excellence.

The 9th annual event returns to Boston in 2024, continuing to support drug developers of all sizes in advancing their novel biotherapeutics discovery and development. Join us to dive into the latest industry innovations, highlighting methods and best practices to automate and streamline data collection, integrate experimental data, and leverage state-of-the-art deep learning models for the progression of novel, complex biologics pipelines.

Dates: October 22 – 24, 2024

Location: Hilton Boston Back Bay, Boston, MA

Event Program: https://ter.li/fs8904

With fresh new content covering computational and structural biology, together with protein and antibody engineering, here’s what you can look forward to at this year's event:

• Hear the latest cutting-edge work from the Baker Lab, renowned for its ground-breaking work in protein design and engineering
• Cut through the hype and hear real-world case studies where AI has generated novel biologics with Absci & AI Proteins
• Discover how to better integrate computational tools into the discovery pipeline to harness their potential to translate initial hits into clinical and preclinical stages with Boehringer Ingelheim
• Strategies for streamlining and automating data collection to enable continuous machine learning AbbVie & Takeda
• Uncover how computational tools can improve mechanistic understanding of degradation and higher order structural characterization of biologics with Bristol Myers Squibb

Download the agenda here: https://ter.li/fs8904

Register your place here (and take advantage of group discounts of up to 20% when sending your team of three or more!): https://ter.li/k9kylq